H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $34 from $40 and keeps a Buy rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback